The ASCO Post

News and views from the world of clinical oncology and hematology

[The ASCO Post @ASCOPost]

🖥️ #ASCOAI: Could #AI improve clinical trial recruitment?

At #ASCOQLTY26, @ravi_b_parikh & So Hee Ahn, BS, MS, discuss how a neurosymbolic AI model improved prescreening efficiency, inclusivity for a phase III #ProstateCancer trial.

🎥 Watch the video 👉https://t.co/YPPLAgbyog

[The ASCO Post @ASCOPost]

🚺 Phase III TroFuse-005 results show that sacituzumab tirumotecan significantly improved progression-free and overall survival vs standard chemotherapy in previously treated advanced or recurrent #EndometrialCancer.

▪️@mdslightfoot & @BPothuri | #ESMO26

https://t.co/g6h2T1opaJ

[The ASCO Post @ASCOPost]

🫁 Phase 3️⃣ Krascendo 1 results show improved survival with divarasib in previously treated advanced KRAS G12C–mutated #NSCLC.
Compared with sotorasib or adagrasib, divarasib reduced the risk of progression by 42% and death by 44%.
🔸@FSkoulidis | #ESMO26
https://t.co/7RmdoOsJ59

[The ASCO Post @ASCOPost]

💊Phase 3️⃣ EMT2 study: high-dose omega-3 EPA was associated with improved 5-year OS rates after surgery for #ColorectalCancer liver metastases (62% vs 45.1% with placebo), but did not improve PFS. Further study warranted.
🗣️Presented @mark_tbh | #ESMO26
🔗 https://t.co/FOjTf8txaN

[The ASCO Post @ASCOPost]

🥼#ASCOAI: How are clinicians using #AI?

A JAMA study analyzed 271 million @OpenEvidence queries from 952,008 US clinicians, finding high relative use among #oncology, #hematology physicians.

➡️ Use driven by real clinical decision support

Learn more:️ https://t.co/5lTKvuq78l

[The ASCO Post @ASCOPost]

🚺 Combining immunotherapy and targeted therapy may improve long-term outcomes in advanced #EndometrialCancer.

Phase 3️⃣ DUO-E: showed survival benefits with durvalumab + olaparib, including in patients with pMMR tumors.

▪️@ShannonWestin | #ESMO26

🔗https://t.co/qAW6Kl4chE

[The ASCO Post @ASCOPost]

🫁 New #ESMO26 data show improved local control with radiotherapy in oligometastatic #NSCLC.
In SARON, median progression-free survival was prolonged by 56% with radiotherapy + systemic therapy.
✅ Similar QOL
🗣️ Dr. Fiona McDonald (@fifimcdrmh)
🔗 https://t.co/vQ5lWOkRgt

[The ASCO Post @ASCOPost]

📱#ASCOAI: Human-supervised #AI could support nurse-led #oncology triage by identifying low-acuity calls and drafting clinical notes.
➡️ LLMs generated documentation faster than trainees, but prospective validation is needed.
🔗 https://t.co/vRt9wPJRHT
#ASCOQLTY26 #AIinOncology

[The ASCO Post @ASCOPost]

🧬 Despite higher rates of cardiovascular and kidney disease, adults with #Diabetes and a history of #Cancer reported lower use of injectable GLP-1 RAs.

🔸Bismarck C. Odei, MD | @JAMANetworkOpen

Explore the findings ➡️ https://t.co/KgIp76rLOI

[The ASCO Post @ASCOPost]

💉Phase III INTerpath-001 trial: A personalized mRNA cancer vaccine plus pembrolizumab reduced the risk of recurrence or death by 42% vs pembrolizumab alone in patients with high-risk #Melanoma after surgery.

▪ @ProfGLongMIA | #ESMO26 | @myESMO

🔗 https://t.co/9c5Ja6GpBq

[The ASCO Post @ASCOPost]

🚹 Triplet therapy improved long-term survival in metastatic castration-sensitive #ProstateCancer.

In PEACE-1, 8-year OS was 40.3% with abiraterone + ADT ± docetaxel vs 27.1% with standard therapy alone.

🔹Karim Fizazi, MD, PhD | | #ESMO26 | @myESMO

🔗 https://t.co/rp1d3mvUxU

[The ASCO Post @ASCOPost]

📝 #ASCOAI: Ambient #AI scribes are entering oncology workflows, but adoption varies.

New @ClevelandClinic data highlight differences in use among medical oncology, hematology, and radiation oncology clinicians from a large-scale deployment.

🔗️ https://t.co/xZgCfwBup6

[The ASCO Post @ASCOPost]

💻Expanding access to oncology expertise could help address gaps in #CancerCare.

New findings suggest remote expert case reviews can identify opportunities to improve treatment, including for patients in nonurban settings.

🔹Debra Wong, MD | #ASCOQLTY26

https://t.co/tyjNgeDr9p

[The ASCO Post @ASCOPost]

🩸New phase III VERIFY findings highlight rusfertide benefits in patients with #PolycythemiaVera:

⬆️Improved hematocrit control
📉Fewer phlebotomies
⬇️Reduced fatigue and symptom burden

🥼@KuykendallMd | @JCO_ASCO | #MPNsm
🔗 https://t.co/KkzAVpxHH1

[The ASCO Post @ASCOPost]

🚨 #FDAApproval: The @FDA has granted approval for talazoparib (Talzenna) + enzalutamide for adults with HRR-mutated metastatic androgen pathway modulation–naive/sensitive #ProstateCancer.

Approval supported by findings from the TALAPRO-3 trial.

🔗 https://t.co/9EE3mzuycC

[The ASCO Post @ASCOPost]

🏆 @theNAMedicine has elected 100 new members for 2026, recognizing outstanding contributions to medical science, health care, and public health.

🌐 The new class includes 90 U.S. and 10 international members.

Meet the inductees ➡️ https://t.co/GP307bodK6

[The ASCO Post @ASCOPost]

🚭 Financial incentives may improve smoking cessation among patients referred for #LungCancer screening.

In a trial of 3,259 underserved adults, sustained abstinence rates were 8.8% with incentives vs 4.3% with usual care.

▪���@JHartMD | @JAMANetwork
🔗 https://t.co/wOVQ8IhGFs

[The ASCO Post @ASCOPost]

Catch up on the latest #AI in #oncology news:
🔹 @FDA-cleared #BreastCancer risk tool
🔹LLMs in oncology telephone triage
🔹Chatbot improves hereditary #cancerrisk awareness

🎥 Watch this week's brief: https://t.co/iZXoEYIL8k

[The ASCO Post @ASCOPost]

🌎 Geographic disparities limit access to #BreastCancer clinical trials.

A new study found that 76% of U.S. counties had no active TNBC trials, highlighting significant gaps in research access.

🔹Research from @UTMDAnderson & @ASCO

https://t.co/qk8D1GCDB6

[The ASCO Post @ASCOPost]

🧫 The NRG-BR002 trial found that adding metastasis-directed ablation to first-line systemic therapy did not significantly improve progression-free or overall survival in patients with oligometastatic #BreastCancer.

▪️Steven J. Chmura, MD, PhD | @JCO_ASCO
https://t.co/oCjUrcgt0G